Ehm2 transcript variant 1 inhibits breast cancer progression and increases E-cadherin stability. (24th November 2022)

• Record Type: Journal Article
• Authors: Yin, Xin; Li, Gen; Fan, Dongwei; Ge, Zhicheng; Yang, Tianshu; Shang, Yaxin; Ma, Tianyu; Yuan, Baowen; Huang, Wei; Teng, Xu; Yu, Hefen
• Is Part Of: Carcinogenesis. Volume 43:Number 12(2022)
• Page Start: 1110
• Page End: 1120
• Publication Date: 2022-11-24
• Subjects: Carcinogenesis -- Periodicals; Cancer -- Genetic aspects -- Periodicals; Cancer -- Prevention -- Periodicals; Cancer -- Periodicals; 616.994071
• DOI: 10.1093/carcin/bgac076
• Languages: English
• ISSNs: 0143-3334

Abstract

Abstract: Ehm2/1, an Ehm2 transcript variant, regulates the cytoskeleton by binding to plasma membrane proteins. However, the role of Ehm2/1 in breast cancer development remains poorly understood. This study shows that, the expression of Ehm2/1 was decreased in breast cancer and that patients with low Ehm2/1 expression had a significantly poorer prognosis than those with high expression of Ehm2/1. Overexpression of Ehm2/1 in MCF-7 breast cancer cells inhibited cell migration and invasion. Ehm2/1 markedly increased the stability and half-life of E-cadherin. Moreover, Ehm2/1 was collocated with E-cadherin in the plasma membrane of MCF-7 cells. Furthermore, downregulation of Ehm2/1 promoted ubiquitination of E-cadherin, whereas overexpression of Ehm2/1 inhibited ubiquitination of E-cadherin. These results suggest that Ehm2/1 could suppress the migration and invasion of breast cancer cells by increasing E-cadherin stability. Abstract : Ehm2/1 was significantly lower in patients with breast cancer who had a poor prognosis. Ehm2/1 increased the stability of E-cadherin by inhibiting its polyubiquitination and proteasomal degradation and could suppress the migration and invasion of breast cancer cells. Graphical abstract: